Compare Mercadolibre Inc (MELI) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Philip Morris International Inc. — how do they compare? Mercadolibre Inc trades at $1,860.11 (market cap $94.13B), while Philip Morris International Inc. trades at $200.36 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 3.3× Mercadolibre Inc's market cap, and Philip Morris International Inc. pays a 3.19% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 117 Days and Philip Morris International Inc. for 85 Days on average.
| MELI | PM | |
|---|---|---|
Market Cap | $94.13B | $312.50B |
Volume | 273,781 | 5,517,172 |
Sector | Consumer Cyclical | Consumer Staples |
52-Week High | $2.36K | $200.50 |
52-Week Low | $1.55K | $144.33 |
Typical Hold Time | 117 Days | 85 Days |
Enterprise Value | $101.77B | $355.62B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,872.78, up 0.8% on the day, with a bullish technical signal and strong analyst consensus. Revenue growth remains robust, reaching $28.89 billion in 2025, though net income margins have softened. Recent news highlights expansion in Brazil, including one-hour delivery and pharmacy services, while the fintech ecosystem strengthens with a 75% surge in credit portfolio.
The outlook is positive given dominant market position and growth initiatives, but risks include macroeconomic headwinds in Latin America and elevated valuation multiples. Analyst price targets average $2,170, suggesting potential upside, supported by institutional buying interest.
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
